Association between cyclooxygenase-2 and matrix metalloproteinase-2 expression in non-small cell lung cancer

Japanese Journal of Clinical Oncology

Volumn 36, Issue 5, 2006, Pages 263-268

  Byun, Jae Ho ^a   Lee, Myung Ah ^a   Roh, Sang Young ^a   Shim, Byoung Yong ^a   Hong, Sook Hee ^a   Ko, Yoon Ho ^a   Ko, Su Jin ^a   Woo, In Sook ^a   Kang, Jin Hyoung ^a   Hong, Young Seon ^a   Lee, Kyung Shik ^a   Lee, Ah Won ^a   Park, Gyeong Sin ^a   Lee, Kyo Yeong ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Cyclooxygenase 2; Matrix metalloproteinase 2; Non small cell lung cancer

Indexed keywords

CYCLOOXYGENASE 2; GELATINASE A; MATRIX METALLOPROTEINASE; PROTEINASE;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER CLASSIFICATION; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; METASTASIS POTENTIAL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL ANALYSIS;

EID: 33745686438     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyl024     Document Type: Article

References (33)

1. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000;89:2637-45.
2. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997;57:1276-80.
3. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998;58:4997-5001.
4. Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999;59:987-90.
5. Bae SH, Jung ES, Park YM, Kim BS, Kim BK, Kim DG, et al. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. Clin Cancer Res 2001;7:1410-8.
6. Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 2002;190:279-86.
7. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-11.
8. Cianchi F, Cortesini C, Bechi P, Fantappie O, Messerini L, Vannacci A, et al. Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 2001;121:1339-47.
9. Subbaramaiah K, Telang N, Ramonetti JT, Araki R, DeVito B, Weksler BB, et al. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res 1996;56:4424-9.
10. Ledro Cano D, Gomez Rodriguez BJ, Torres Dominguez Y, Hergueta Delgado P, Herrerias Esteban JM, Herrerias Gutierrez JM [Non-steroidal anti-inflammatory drugs and cyclooxygenase-2 selectivity in gastroenterology]. Rev Esp Enferm Dig 1999;91:305-9.
11. Sun WH, Sun YL, Fang RN, Shao Y, Xu HC, Xue QP, et al. Expression of cyclooxygenase-2 and matrix metalloproteinase-9 in gastric carcinoma and its correlation with angiogenesis. Jpn J Clin Oncol 2005;35:707-13.
12. Achiwa H, Yatabe Y, Hida T, Kuroishi T, Kozaki K, Nakamura S, et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999;5:1001-5.
13. Khuri FR, Wu H, Lee JJ, Kemp BL, Lotan R, Lippman SM, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001;7:861-7.
14. Brabender J, Park J, Metzger R, Schneider PM, Lord RV, Holscher AH, et al. Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer. Ann Surg 2002;235:440-3.
15. Yurchenco PD, Schittny JC. Molecular architecture of basement membranes. Faseb J 1990;4:1577-90.
16. Liotta LA, Rao CN, Barsky SH. Tumor invasion and the extracellular matrix. Lab Invest 1983;49:636-49.
17. Aznavoorian S, Murphy AN, Stetler-Stevenson WG, Liotta LA. Molecular aspects of tumor cell invasion and metastasis. Cancer 1993;71:1368-83.
18. Brown PD, Bloxidge RE, Stuart NS, Gatter KC, Carmichael J. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst 1993;85:574-8.
19. Gonzalez-Avila G, Iturria C, Vadillo F, Teran L, Selman M, Perez-Tamayo R. 72-kD (MMP-2) and 92-kD (MMP-9) type IV collagenase production and activity in different histologic types of lung cancer cells. Pathobiology 1998;66:5-16.
20. Iizasa T, Fujisawa T, Suzuki M, Motohashi S, Yasufuku K, Yasukawa T, et al. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients. Clin Cancer Res 1999;5: 149-53.
21. Passlick B, Sienel W, Seen-Hibler R, Wockel W, Thetter O, Mutschler W, et al. Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer. Clin Cancer Res 2000;6:3944-8.
22. Ito H, Duxbury M, Benoit E, Clancy TE, Zinner MJ, Ashley SW, et al. Prostaglandin E2 enhances pancreatic cancer invasiveness through an Ets-1-dependent induction of matrix metalloproteinase-2. Cancer Res 2004;64:7439-46.
23. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997;94:3336-40.
24. Travis WD, Colby TD, Corrin B. Histologic Typing of Lung and Pleural Tumors. 3rd edn. Berlin: Springer-Verlag 1999.
25. Stetler-Stevenson WG. Invasion and metastases. In: DeVita, Jr VT, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology. Philadelphia, PA: LWW 2005;113-27.
26. Yao M, Kargman S, Lam EC, Kelly CR, Zheng Y, Luk P, et al. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res 2003;63:586-92.
27. Pan MR, Chuang LY, Hung WC. Non-steroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 expression via repression of transcription in lung cancer cells. FEBS Lett 2001;508:365-8.
28. Miyata Y, Koga S, Kanda S, Nishikido M, Hayashi T, Kanetake H. Expression of cyclooxygenase-2 in renal cell carcinoma: Correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin Cancer Res 2003;9:1741-9.
29. Sivula A, Talvensaari-Mattila A, Lundin J, Joensuu H, Haglund C, Ristimaki A, et al. Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res Treat 2005;89:215-20.
30. Ishikawa S, Takenaka K, Yanagihara K, Miyahara R, Kawano Y, Otake Y, et al. Matrix metalloproteinase-2 status in stromal fibroblasts, not in tumor cells, is a significant prognostic factor in non-small cell lung cancer. Clin Cancer Res 2004;10:6579-85.
31. Stamenkovic I. Extracellular matrix remodelling: The role of matrix metalloproteinases. J Pathol 2003;200:448-64.
32. Marrogi AJ, Travis WD, Welsh JA, Khan MA, Rahim H, Tazelaar H, et al. Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res 2000;6:4739-44.
33. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998;58: 3761-4.